MDT perspectives on the role of biomarkers in informing immune checkpoint inhibitor use across tumour types

touchMDT for touchONCOLOGY

Listen to key experts from a multidisciplinary team review the role of biomarkers in informing immune checkpoint inhibitor use across tumour types.

The multidisciplinary team

• Medical oncologist: Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan
• Pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Heidelberg, Germany

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from MSD. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/immune-checkpoint-inhibitors-in-solid-tumours/